Glucotrack, Inc.
Close on Oct 19, 2026
- Market cap
- $3.43M
- P/E (TTM)
- 0.0
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | After market close | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 30, 2026 | After market close | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 13, 2025 | After market close | – | $-4.64 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 14, 2025 | After market close | – | $-0.67 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | After market close | – | – | – |
Press releases
Announcements Glucotrack filed with the SEC
Inc. Announces Pricing of $3 Million Public Offering
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics™ and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai² Platform Growth and Clinical Development
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Announces Reverse Stock Split
Regulation FD disclosure · EX-99.1 to Form 8-K
$2.0 Million Equity Financing at $0.75 Per Unit, priced at a premium to the market, and $3.5 Million Follow-On Investment from Institutional
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics™ Advances LT-100 Development Strategy Toward Single-Injection Administration
Regulation FD disclosure · EX-99.1 to Form 8-K
and Lōkahi Therapeutics Complete Strategic Business Combination, Establishing Lōkahi-Controlled Public Platform
Material agreement · Acquisition or disposition completed · New financial obligation · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Announces IDE Submission for U.S. Clinical Study of its Novel Implantable Continuous Blood Glucose Monitoring Technology
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Material agreement · New financial obligation · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Announces Publication of Peer-Reviewed Study In The Journal of Diabetes Research Demonstrating Long-Term Accuracy and Stability
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Fourth Quarter and Full Year 2025
Results of operations · EX-99.1 to Form 8-K
to File Significant IDE with FDA for US Clinical Trial in Early Q2 Based on Critical 2025 Milestones
Regulation FD disclosure · EX-99.1 to Form 8-K
ANNOUNCES USPTO APPROVAL FOR ISSUANCE OF PATENTS FOR PROPRIETARY CBGM PLATFORM
Regulation FD disclosure · EX-99.1 to Form 8-K
Inc. Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Institutional Investor
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Third Quarter 2025 Financial Results and Provides Update on Recent Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Inc. Encourages Shareholders to Vote
Regulation FD disclosure · EX-99.1 to Form 8-K
APPOINTS NEUROMODULATION AND PAINFUL DIABETIC NEUROPATHY EXPERT, USMAN LATIF, MD, MBA, TO CLINICAL ADVISORY TEAM
Regulation FD disclosure · EX-99.1 to Form 8-K
Special Meeting of Shareholders held on October 31, 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EXPANDS CLINICAL ADVISORY TEAM APPOINTING DAVID S. HIRSH, MD AS MEDICAL DIRECTOR, CARDIOLOGY
Regulation FD disclosure · EX-99.1 to Form 8-K
TO EXHIBIT AT 2025 ASSOCIATION OF DIABETES CARE AND EDUCATION SPECIALISTS ANNUAL MEETING
Regulation FD disclosure · EX-99.1 to Form 8-K
ANNOUNCES REPURCHASE OF SERIES A WARRANTS
Regulation FD disclosure · EX-99.1 to Form 8-K
AND ONETWO ANALYTICS PRESENT POSITIVE FINAL RESULTS
Regulation FD disclosure · EX-99.1 to Form 8-K
Approved Action Meets NASDAQ Panel Hearing Listing Requirements
Regulation FD disclosure · EX-99.1 to Form 8-K
TO SHOWCASE LONG-TERM CONTINUOUS BLOOD GLUCOSE MONITOR AT AMERICAN DIABETES ASSOCIATION’S 85TH SCIENTIFIC SESSIONS
Regulation FD disclosure · EX-99.1 to Form 8-K
ESTABLISHES PATIENT ADVISORY BOARD TO INFORM DIABETES TECHNOLOGY DEVELOPMENT
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports First Quarter 2025 Financial Results and Recent Corporate Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
ANNOUNCES ETHICAL APPROVAL FOR LONG-TERM CLINICAL STUDY OF CONTINUOUS BLOOD GLUCOSE MONITOR
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
TO PARTICIPATE IN FORGETDIABETES, A PROMINENT EUROPEAN RESEARCH INITIATIVE TO DEVELOP A BIONIC PANCREAS
Regulation FD disclosure · EX-99.1 to Form 8-K
AND ONETWO ANALYTICS TO COLLABORATE FOR CLINICAL STUDY ANALYSIS ON ITS CONTINUOUS BLOOD GLUCOSE MONITOR
Regulation FD disclosure · EX-99.1 to Form 8-K
Reports Full Year 2024 Financial Results and Recent Corporate Highlights
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
TO PRESENT FIRST-IN-HUMAN STUDY RESULTS FOR CONTINUOUS BLOOD GLUCOSE MONITOR AT THE 2025 INTERNATIONAL CONFERENCE ON ADVANCED TECHNOLOGIES
Regulation FD disclosure · EX-99.1 to Form 8-K
APPOINTS GUILLERMO UMPIERREZ, MD, CDCES, FACE, MACP
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Glucotrack, Inc. Announces Pricing of $3.0 Million
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
ANNOUNCES SUCCESSFUL COMPLETION OF ITS FIRST HUMAN CLINICAL STUDY OF CONTINUOUS BLOOD GLUCOSE MONITOR
Charter or bylaw amendment · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
reverse stock split to become effective as of the opening of trading on
Regulation FD disclosure · EX-99.1 to Form 8-K